Transbio Forum closes with more than 200 meetings seeking collaborations in molecular medicine and agrofood innovation
The first partnership is the Vall d’Hebron Research Institute with Pierre Fabre, which have patented a new therapy to promote vasculogenesis after an acute myocardial infarction.
By Biocat
The Transbio Emergence Forum has closed its doors in Montpellier with more than 200 meetings held among companies, research centers, technology transfer offices and science-technology platforms from Catalonia and the seven other regions in southwest Europe seeking out collaboration on R&D&i projects in molecular medicine and agrofood.
In order to support joint projects between Catalonia and other regions that may arise after the Forum in Montpellier, the Transbio project will provide travel and intellectual-property grants. Companies and organizations interested should contact Biocat (acasta@biocat.cat).
The event, held 25 to 27 September, was organized by the partners from the regions in France, Portugal and Spain that are collaborating on the Transbio Interreg Sudoe project (2013-2014) to promote the transfer of health sciences research to market. From Catalonia, the partners are Biocat, the Barcelona Science Park (PCB), the UAB Research Park and CataloniaBIO.
Both molecular medicine and agrofood innovation are areas with high scientific and business potential in Catalonia. Over the past ten years, the country has become a benchmark in biomedical research and various centers and public hospitals have included molecular medicine into their programs to improve prognostics and the prevention of cardiovascular, respiratory, oncologic and vision diseases, among others.
The Vall d’Hebron Research Institute (VHIR) is one of them. At the Transbio Emergence Forum, VHIR presented a new gene therapy, based on encapsulated anti-microRNA, to promote vasculogenesis in tissue damaged by acute myocardial infarctions. This new technology is in the preclinical development phase and has been patented jointly by Dr. David Garcia-Dorado, head of the VHIR Cardiocirculatory Pathology group, and French pharmaceutical company Pierre Fabre. It is the first partnership to come out of the Transbio project.
Companies Oryzon and Aniling and the Leitat technology center also participated in the program of pitch sessions, which dealt with the latest breakthroughs in molecular medicine to improve molecular diagnostic techniques for personalized medicine and drug development for diseases like leukemia.
In the agrofood track, the Center for Research in Agricultural Genomics (CRAG), Laboratoris Ordesa and the Rovira i Virgili University Technological Center of Nutrition and Health (CTNS) presented their cutting-edge technology capabilities in the field of childhood nutrition and applied agricultural research.
The PCB Drug Discovery Platform explained their research-support services and the VHIR TTO, their portfolio of 16 patents available for licensing.
Over the coming months, Transbio will continue with several meetings on how to attract funding for innovative companies and workshops on Ion Mobility Spectrometry in Bordeaux (24 and 25 October) and Metabolomics and Molecular Interactions for Biology and Health (13 November) in Oeiras. The next large-scale meeting of the business and science community, however, will be in Barcelona in March 2014 at the second edition of the Transbio Emergence Forum.
Follow the forum on Twitter with the hashtag #Transbio.
Related news (29 August 2013)
Questions:
Biocat Business Development Area
Dr. Alex Casta (Head of Innovation and Technology Transfer)
acasta@biocat.cat
Tel. +34 93 310 33 89
| Organized by: |
|
